keyboard_arrow_up

5EU Prophylactic Hepatitis B Virus Vaccines, Drug Market Analysis and 2022 Forecast

RnRMarketResearch.com adds report “PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – 5EU Drug Forecast and Market Analysis to 2022” to its store.

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines – 5EU Drug Forecast and Market Analysis to 2022

Summary

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Request a sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=164947 .

GlobalData’s primary and secondary research has revealed that the reimbursement of Infanrix Hexa, which began in 2008, has helped France’s routine HBV immunization program recover from safety concerns (CTV, 2012; Denis et al., 2013). The adult HBV vaccine market in Germany is also expected to grow during the forecast period, led by the arrival of Dynavax Technologies’ Heplisav in the second half of 2018. GSK dominated Italy’s HBV vaccine market in 2012. Sanofi Pasteur MSD’s monovalent vaccine, HBVaxPro, accounted for the remaining market share. More specifically, GlobalData expects the arrival of Sanofi Pasteur MSD’s Hexyon to be the principal driver of Spain’s market growth, as it should compete with Infanrix Hexa for market share in the routine immunization program. GlobalData’s primary research has revealed that challenging barriers to growth, such as poor funding mechanisms due to government spending concerns, inadequate physician education, and low patient awareness, will limit adult vaccine uptake and growth of this segment of the market in the UK.

Scope

- Overview of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Hepatitis B disease market.

Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-prophylactic-hepatitis-b-virus-vaccines-5eu-drug-forecast-and-market-analysis-to-2022-market-report.html .

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in 5EU

Inquire for discount on this report @ http://www.rnrmarketresearch.com/contacts/discount?rname=164947 .

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 10
1.2 List of Figures 13
2 Introduction 14
2.1 Catalyst 14
2.2 Related Reports 15
2.3 Upcoming Related Reports 17
3 Disease Overview 18
3.1 Overview 18
3.2 Etiology and Pathophysiology 19
3.2.1 Etiology 19
3.2.2 Pathophysiology 22
3.3 Symptoms 24
3.4 Prognosis 26
4 Vaccination Recommendations and Coverage Rates 27
4.1 Overview 27
4.2 France 30

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=164947 .

Browse Hepatitis Drugs Industry Reports @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hepatitis-drugs .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more.

Follow Us On

Twitter : https://twitter.com/#!/RnRMR

Facebook : http://www.facebook.com/pages/RnR-Market-Research/413488545356345

Google Plus : https://plus.google.com/u/0/104156468549256253075/